Which medications and support are anticipated for a patient with COPD who develops ARDS?

• A. Bronchodilators, corticosteroids, BiPAP
• B. Antibiotics, diuretics, supplemental oxygen
• C. Immunotherapy, chemotherapy
• D. Endotracheal intubation and possible surgery

Answer: (A)

In a COPD patient who develops ARDS, the focus is on supporting ventilation while addressing the COPD-related airway inflammation and obstruction. Bronchodilators open up the airways, making it easier to move air in and out and reducing the work of breathing. Corticosteroids help quell airway inflammation and are commonly used during COPD exacerbations to improve symptoms and oxygenation. Noninvasive ventilation with BiPAP provides positive pressure support to improve gas exchange and reduce the effort required to breathe, which can help stabilize the patient without immediate intubation. Together, these treatments target airway patency, inflammatory response, and ventilation support, which is why they form the best match for the scenario.

Antibiotics and diuretics may be appropriate in specific situations (such as infection or fluid overload), but they don’t address the core needs of airway patency, inflammation control, and noninvasive ventilation support in this context. Immunotherapy or chemotherapy are not part of standard management for COPD with ARDS, and while intubation may eventually be necessary if respiratory failure worsens, the scenario described emphasizes noninvasive ventilation and airway-directed therapy as the appropriate initial plan.